A- A A+

Sanofi Kompendium Substitutionsmedizin – Neuauflage 2018

Das neue Kompendium Substitutionsmedizin bietet allen Ärzten, die in der Praxis mit Suchtmedizin zu tun haben, einen umfassenden Einblick in die verschiedenen Aspekte der Opiatsubstitutionstherapie. Das Kompendium wurde erweitert um die aktuelle Rechtslage und richtet sich auch an ApothekerInnen als zusätzliche Zielgruppe

Das Kompendium kann aufgerufen und runtergeladen werden auf der Substitutionsseite von Sanofi. Die Druckausgabe kann über den Außendienst von Sanofi bestellt werden.

https://www.substitutionsportal.de/

One size does not fit all – evolution of opioid agonist treatments in a naturalistic setting over 23 years.

Nordt, C., Vogel, M., Dey, M., Moldovanyi, A., Beck, T., Berthel, T., Walter, M., Seifritz, E., Dürsteler, K. M., and Herdener, M. (2018) 

Addiction, doi.org/10.1111/add.14442.

Abstract

https://onlinelibrary.wiley.com/doi/10.1111/add.14442

Unsupervised Intake of Medicines for Individuals in Opioid Maintenance [Internet].

Hov L, Mosdøl A, Ding Y, Strømme H, Vist GE.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2016 Sep.

https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0098764/

SAMHSA. Medications for opioid use disorder: for healthcare and addiction professionals, policymakers, patients, and families: Treatment Improvement Protocol: TIP 63.

Substance Abuse and Mental Health Services Administration 
[US] Substance Abuse and Mental Health Services Administration, 2018

https://store.samhsa.gov/shin/content/SMA18-5063FULLDOC/SMA18-5063FULLDOC.pdf

Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial.

Bansback, N., Guh, D., Oviedo-Joekes, E., Brissette, S., Harrison, S., Janmohamed, A., Krausz, M., MacDonald, S., Marsh, D. C., Schechter, M. T., and Anis, A. H. (2018)

Addiction, doi: 10.1111/add.14171.

Abstract

https://onlinelibrary.wiley.com/doi/abs/10.1111/add.14171

Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study.

Larney S, Hickman M, Fiellin DA, Dobbins T, Nielsen S, Jones NR, Mattick RP, Ali R, Degenhardt L.

BMJ Open. 2018 Aug 5;8(8):e025204. doi: 10.1136/bmjopen-2018-025204.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078240/

Neue Auflage: Leitfaden für Ärzte zur substitutionsgestützten Behandlung Opiatabhängiger (Bayerische Akademie für Sucht- und Gesundheitsfragen)

Die 4. vollständig überarbeitete Auflage der BAS-Publikation "Leitfaden für Ärzte zur substitutionsgestützten Behandlung Opiatabhängiger" steht Ihnen ab sofort zum Download zur Verfügung.
Hierbei wurden die neue BtMVV (2017) sowie die überarbeiteten Richtlinien der Bundesärztekammer (2017) berücksichtigt. (BAS, Januar 2018)

http://www.bas-muenchen.de/fileadmin/documents/pdf/Publikationen/Papiere/BAS_Substitutionsleitfaden_final_2018_1.pdf

Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial.

Zhu Y, Evans EA, Mooney LJ, Saxon AJ, Kelleghan A, Yoo C, Hser YI.

J Neuroimmune Pharmacol. 2018 Aug 9. doi: 10.1007/s11481-018-9801-x.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/30094695

Handbuch Substitutionsbehandlung in Oberösterreich

Sachverständigenkommission zur regionalen Koordination der Substitutionsbehandlung

Linz, 2016, Version 2.0

https://www.land-oberoesterreich.gv.at/Mediendateien/Formulare/DokumenteAbt_San/Ges_Handbuch_Substitutionsbehandlung.pdf

USA. FDA takes new steps to encourage the development of novel medicines for the treatment of opioid use disorder

The U.S. Food and Drug Administration today issued new scientific recommendations aimed at encouraging more widespread innovation and development of novel medication-assisted treatment (MAT) drugs for the treatment of opioid use disorder (OUD). New draft guidance issued today outlines new ways for drug developers to consider measuring and demonstrating the effectiveness and benefits of new or existing MAT products. This new draft guidance is part of the FDA’s ongoing commitment to promote more widespread development, access to and adoption of MAT. (FDA, 06.08.2018)

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm615892.htm

Treatment and Prevention of Opioid Use Disorder: Challenges and Opportunities

Dennis McCarty, Kelsey C. Priest, P. Todd Korthuis

Annual Review of Public Health 2018 39:1

http://www.annualreviews.org/doi/pdf/10.1146/annurev-publhealth-040617-013526

Pharmacological therapies for management of opium withdrawal.

Rahimi-Movaghar A, Gholami J, Amato L, Hoseinie L, Yousefi-Nooraie R, Amin-Esmaeili M.

Cochrane Database Syst Rev. 2018 Jun 21;6:CD007522. doi: 10.1002/14651858.CD007522.pub2. Review.

Abstract

http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD007522.pub2/abstract;jsessionid=D03C45BCE0AA96B3C23A7429866E7E43.f01t03

Tramadol for maintenance in opioid dependence: A retrospective chart review.

Sarkar S, Lal R, Varshney M, Balhara YPS.

J Opioid Manag. 2017 Sep/Oct;13(5):329-334. doi: 10.5055/jom.2017.0401.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/29199398

Snake Venom Use as a Substitute for Opioids: A Case Report and Review of Literature.

Mehra A, Basu D, Grover S.

Indian J Psychol Med. 2018 May-Jun;40(3):269-271. doi: 10.4103/IJPSYM.IJPSYM_216_17.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968650/

Kanada. B.C. pilot project to distribute clean opioids to people at high risk of overdose

Ottawa has approved a pilot project that will allow health officials in B.C. to distribute clean opioids to drug users to use as they please, marking one of the province's most radical efforts to address a fentanyl-saturated drug supply that has killed more than 1,000 people this year. (Globe and Mail, 19.12.2017)

https://www.theglobeandmail.com/news/british-columbia/bc-pilot-project-to-distribute-clean-opioids-to-people-at-high-risk-of-overdose/article37392053

Continuous opioid substitution treatment over five years: Heroin use trajectories and outcomes.

Eastwood B, Strang J, Marsden J.

Drug Alcohol Depend. 2018 May 16;188:200-208. doi: 10.1016/j.drugalcdep.2018.03.052.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/29778774

Betäubungsmittel: Arzneimittel zur Substitution – ein Überblick 

Bei der Substitutionstherapie Opioidabhängiger gibt es eine Reihe zusätzlicher Auflagen. Hier sind vor allem die Regelungen des § 5 der Betäubungsmittelverschreibungsverordnung maßgeblich. Unter anderem finden sich dort Vorgaben, welche Arzneimittel beziehungsweise Wirkstoffe überhaupt für eine Substitutionstherapie verschrieben werden können. In der Praxis stehen sowohl Rezepturen als auch Fertigarzneimittel zur Verfügung. (DAZ – Deutsche Apotheker Zeitung, 11.12.2017)

https://www.deutsche-apotheker-zeitung.de/news/artikel/2017/12/11/arzneimittel-zur-substitution-ein-ueberblick/chapter:1

Opioid substitution treatment and heroin dependent adolescents: reductions in heroin use and treatment retention over twelve months.

Smyth BP, Elmusharaf K, Cullen W.

BMC Pediatr. 2018 May 4;18(1):151. doi: 10.1186/s12887-018-1137-4.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5936020/

Opioid Agonist Treatment Reduces Societal Costs of Crime

Patients with opioid use disorder generated crime-related costs to society at a lower rate while they were in treatment compared with after they left treatment.

Patients who initiate time-unlimited opioid-agonist therapy will generate lower average total crime-related costs over the next 6 months than patients who initiate a 21-day detoxification regimen.

Savings in crime-related costs are substantial and warrant inclusion in cost-effectiveness analyses of treatment for opioid addiction. (NIDA Notes, Eric Sarlin, M.Ed., M.A., 23.08.2017)

https://www.drugabuse.gov/news-events/nida-notes/2017/08/opioid-agonist-treatment-reduces-societal-costs-crime

USA. Lofexidine: FDA approves the first non-opioid treatment for management of opioid withdrawal symptoms in adults

Encouraging more widespread innovation and development of safe and effective treatments for opioid use disorder remains top agency priority. (FDA, USA, 16.05.2018)

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm607884.htm

A systematic review of health economic models of opioid agonist therapies in maintenance treatment of non-prescription opioid dependence.

Chetty M, Kenworthy JJ, Langham S, Walker A, Dunlop WC.

Addict Sci Clin Pract. 2017 Feb 24;12(1):6. doi: 10.1186/s13722-017-0071-3. Review.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5324212/

Effects of medication assisted treatment (MAT) for opioid use disorder on functional outcomes: A systematic review.

Maglione MA, Raaen L, Chen C, Azhar G, Shahidinia N, Shen M, Maksabedian E, Shanman RM, Newberry S, Hempel S.

J Subst Abuse Treat. 2018 Jun;89:28-51. doi: 10.1016/j.jsat.2018.03.001. Epub 2018 Mar 13.

https://linkinghub.elsevier.com/retrieve/pii/S0740-5472(17)30482-8

The impact of cannabis use on patients enrolled in opioid agonist therapy in Ontario, Canada.

Franklyn AM, Eibl JK, Gauthier GJ, Marsh DC (2017)

PLoS ONE12(11): e0187633. doi.org/10.1371/journal.pone.0187633

http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0187633

Characteristics of opioid-maintained clients smoking fentanyl patches: The importance of confirmatory drug analysis illustrated by a case series and mini-review.

Kimergård A, Dunne J, Bøgen A, Hindersson P, Breindahl T.

Drug Test Anal. 2018 Apr 19. doi: 10.1002/dta.2397.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/29675893

Medications for opioid use disorder: bridging the gap in care

Volkow, Nora D

The Lancet , Volume 0 , Issue 0 , Published: 14 November 2017

doi.org/10.1016/S0140-6736(17)32893-3

Abstract

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32893-3/fulltext

USA. Fact Sheet: Medication-Assisted Treatment Improves Outcomes for Patients With Opioid Use Disorder

Overview 

Opioid overdoses cause one death every 20 minutes. Medication-assisted treatment (MAT)—a combination of psychosocial therapy and U.S. Food and Drug Administration-approved medication—is the most effective intervention to treat opioid use disorder (OUD) and is more effective than either behavioral interventions or medication alone. MAT significantly reduces illicit opioid use compared with nondrug approaches, and increased access to these therapies can reduce overdose fatalities. However, MAT is often unavailable to those in need of it because of inadequate funding for treatment programs and a lack of qualified providers who can deliver these therapies.

(Fact Sheet, Substance Use Prevention and Treatment Initiative, 22.11.2016)

http://www.pewtrusts.org/en/research-and-analysis/fact-sheets/2016/11/medication-assisted-treatment-improves-outcomes-for-patients-with-opioid-use-disorder

Alternative Opioid Agonists in the Treatment of Opioid Dependence: A Systematic Review [Internet].

Mosdøl A, Ding KY, Hov L.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2017 Mar 8.

https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0098799/